Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Pedro Augusto Marischka MateusLarissa Akemi KidoRafael Sauce SilvaValéria Helena Alves Cagnon QuiteteFabio MonticoPublished in: The Prostate (2018)
Celecoxib plus nintedanib is an effective antitumor combination against prostate cancer progression in TRAMP mice, showing remarkable efficacy in relation to isolated therapies. Importantly, this efficacy might be due to drug association effect on driving AR and mainly ERα distribution in the prostatic tissue towards benign patterns. In addition, celecoxib and nintedanib impaired the development of a stromal reaction by reducing the recruitment of reactive stroma cells and maintaining a normal smooth muscle cell-rich prostate stroma in TRAMP mice. Collectively, these findings pointed to the beneficial effects of combining anti-inflammatory and antiangiogenic strategies to prevent or delay prostatic tumorigenesis.
Keyphrases
- prostate cancer
- radical prostatectomy
- anti inflammatory
- smooth muscle
- high fat diet induced
- benign prostatic hyperplasia
- idiopathic pulmonary fibrosis
- induced apoptosis
- single cell
- interstitial lung disease
- bone marrow
- skeletal muscle
- metabolic syndrome
- oxidative stress
- cell cycle arrest
- mesenchymal stem cells
- stem cells
- type diabetes
- cell therapy
- emergency department
- cell death
- systemic sclerosis
- adverse drug
- signaling pathway
- endoplasmic reticulum